CAS No. |
1191265-33-4 |
中文名称 |
(4aS,6aR,6bR,8aR,12aR,12bR,14aR,14bS)-11-氰基-2,2,6a,6b,9,9,12a-七甲基-10,14-二氧代-N-(2,2,2-三氟乙基)-1,3,4,5,6,6a,6b,7,8,8a,9,10,12a,12b,13,14,14a,14b-十八氢并四苯-4a(2H)-甲酰胺 |
英文名称 |
(4aS,6aR,6bR,8aR,12aR,12bR,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-N-(2,2,2-trifluoroethyl)-1,3,4,5,6,6a,6b,7,8,8a,9,10,12a,12b,13,14,14a,14b-octadecahydropicene-4a(2H)-carboxamide |
别名 |
CPD3619;CDDO-dhTFEA (RTA dh404);(4aS,6aR,6bR,8aR,12aR,12bR,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-N-(2,2,2-trifluoroethyl)-1,3,4,5,6,6a,6b,7,8,8a,9,10,12a,12b,13,14,14a,14b-octadecahydropicene-4a(2H)-carboxamide;RTA dh404;Olean-1-en-28-amide, 2-cyano-3,12-dioxo-N-(2,2,2-trifluoroethyl)-;RTA dh 404,Nuclear factor-κB,Inhibitor,RTA dh-404,CDDOdhTFEA,Keap1-Nrf2,RTA dh404,Nuclear factor-kappaB,CDDO dhTFEA,CDDO-dhTFEA,inhibit,NF-κB;CDDO-dhTFEA, 10 mM in DMSO |
标准英文名 |
(4aS,6aR,6bR,8aR,12aR,12bR,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-N-(2,2,2-trifluoroethyl)-1,3,4,5,6,6a,6b,7,8,8a,9,10,12a,12b,13,14,14a,14b-octadecahydropicene-4a(2H)-carboxamide |
MDL No. |
MFCD32201037 |
分子式 |
C33H45F3N2O3 |
分子量 |
574.73
|
精确分子量 |
574.34
|
SMILES |
CC1(C)CC[C@]2(C(=O)NCC(F)(F)F)CC[C@]3(C)[C@H](C(=O)C[C@@H]4[C@@]5(C)C=C(C#N)C(=O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2C1 |
标准SMILES |
CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C[C@@H]1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(=O)NCC(F)(F)F |
用途 |
CDDO-dhTFEA (RTA dh404) is used to activate Nrf2 and inhibit the pro-inflammatory transcription factor NF-κB; it restores mean arterial pressure (MAP) in hypertension, upregulates Nrf2 and its target genes, suppresses NF-κB activation and TGF-β signaling, and ameliorates glomerulosclerosis, interstitial fibrosis, and inflammation in rats with chronic kidney disease (CKD). |
InChIKey |
RMYWYZJDSBWZHH-BFGQVZSYSA-N |